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Abstract
Background
Increasing proportions of men diagnosed with prostate cancer in the UK are presenting with
non-metastatic disease. We investigated how treatment trends in this demographic
have changed.
Patient and Methods
Non-metastatic cancers diagnosed from 2000–2010 in the UK Anglian Cancer network
stratified by age and risk group were analysed [n = 10,365]. Radiotherapy [RT] and prosta-
tectomy [RP] cancer specific survival [CSS] were further compared [n = 4755].
Results
Over the decade we observed a fall in uptake of primary androgen deprivation therapy but a
rise in conservative management [CM] and radical therapy [p<0.0001]. CM in particular has
become the primary management for low-risk disease by the decade end [p<0.0001]. In
high-risk disease however both RP and RT uptake increased significantly but in an age de-
pendent manner [p<0.0001]. Principally, increased RP in younger men and increased RT
in men 70y. In multivariate analysis of radically treated men both high-risk disease
[HR 8.0 [2.9–22.2], p<0.0001] and use of RT [HR 1.9 [1.0–3.3], p = 0.024] were significant
predictors of a poorer CSM. In age-stratified analysis however, the trend to benefit of RP
over RT was seen only in younger men [ 60 years] with high-risk disease [p = 0.07]. The
numbers needed to treat by RP instead of RT to save one cancer death was 19 for this
group but 67 for the overall cohort.
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Conclusion
This study has identified significant shifts in non-metastatic prostate cancer management
over the last decade. Low-risk disease is now primarily managed by CM while high-risk dis-
ease is increasingly treated radically. Treatment of high-risk younger men by RP is sup-
ported by evidence of better CSM but this benefit is not evident in older men.
Introduction
The incidence of prostate cancer is rising in the UK and worldwide [1–2]. This rise however
has not been associated with a significant change in cancer death rates. This raises the issue of
how treatment can be tailored to address the complex heterogeneity of the disease and reduce
morbidity from over-treatment. It has been shown that radical therapy of all cancers can result
in significant over-treatment without conferring survival benefit [3]. Conversely, effective radi-
cal treatment can reduce disease progression and improve cancer specific survival [CSS] [4–5].
Another major shift in treatment is the increasing use of Radical Prostatectomy [RP], driven in
part by the introduction of laparoscopic and robotic approaches [6]. RP has indeed been
shown to be an effective treatment with many studies suggesting superiority over other radical
options [7]. There remains however, significant uncertainty on the strength of the evidence for
this benefit.
Many of these developments have only come to light towards the end of the last decade and
the impact on therapy patterns in the UK have not to date been well studied. This is particular-
ly relevant as the UK has been at the forefront of research in the use of active surveillance [AS]
for low risk disease and increased radical treatment for more aggressive disease [5, 8–9]. In this
report, we interrogated a well-annotated cancer registry database to investigate patterns of pri-
mary non-metastatic prostate cancer treatment over the last decade. Our primary interest was
to determine if the uptake of radical therapy had altered over time and how these changes were
influenced by disease and patient characteristics.
Patients and Methods
Patient cohort and data collation
Prostate cancers [ICD10 site: C61] diagnosed in the Anglia Cancer Network area between 2000
and 2010 and registered by the National Cancer Registration Service—Eastern Office [NCRS
(E)] were interrogated for this study. Data elements recorded by NCRS[E] include non-
identifiable patient demographics, TNM [fifth edition to 2009 and seventh edition in 2010]
stage, Gleason grade, PSA and details of treatment administered. Recent reports have
highlighted the completeness of staging information at NCRS[E] [10]. No personal informa-
tion or patient identifiable data was obtained or used for this study at any stage. The data was
analysed completely anonymously. As a result no formal ethics was necessary for this study.
From this cohort we identified all men who presented with non—metastatic disease. Risk
groups were ascribed based on the NICE guidelines criteria [2]. Electronic death notifications
were received from the Office of National Statistics. Vital status was also checked using the
Health and Social Care Information Centre Personal Demographics Service batch tracing sys-
tem http://systems.hscic.gov.uk/demographics/pds/]. Cause of death was classified as prostate
cancer specific when listed in Cause 1[a], 1[b], or 1[c] of the death certificate, except when a
markedly worse prognosis cancer was listed in Cause 1[a]. Survival times were calculated from
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the date of diagnosis to date of death or date of censorship [30 September 2013]. The median
follow up was 6.9 years.
Treatments
We focused on 4 therapy modalities; Radical Prostatectomy [RP], External beam radiotherapy
[RT], primary androgen deprivation therapy [PADT] and conservative management [CM].
The first documented mode of management within one year of diagnosis was assigned as the
primary treatment. CM included men on both active surveillance and watchful waiting as the
registry recorded both these treatment modalities as “Watch policy”. This was distinct from
cases where there was missing data on treatments received. External beam radiotherapy within
one year of diagnosis in cases with non-metastatic cancer [with or without androgen depletion]
was considered as radical radiotherapy. Notably 88.2% of patients treated with primary radio-
therapy also had concurrent androgen deprivation therapy though we were not able to deter-
mine the duration of ADT or radiotherapy dose.
Statistical analysis
Annual incidence rates [IR] per 100,000 were calculated with each treatment for the whole
group and then stratified by age and risk groups. Overall, age and risk group specific incidence
curves were then plotted for visual trends. To compute incidence rates we summed cases and
population between 2000–2005 and 2006–2010 and then calculated for five year rates. Differ-
ence in incidence rate ratio [IRR] between the two periods, the standard error and confidence
interval for IRR were calculated using EpiBasic software [http://www.folkesundhed.au.dk/
uddannelse/software]. To compare mortality rates between RP and RT, we computed the pros-
tate cancer mortality rate difference [MRD] per 100,000 person-days [P-D] for each group and
then stratified by age and risk group [EpiBasic software]. p<0.05 was considered statistically
significant different for both analysis. Cox regression analyses was performed to build a predic-
tive model for time-to-event data using R Commander plug-in EZR [Easy R] version 1.23 [1]
and IBM SPSS 20. Test assumptions of proportional Hazard ratio [PH] by visual and rho
chi-square were also performed and all the test results met the PH assumption. Finally, we cal-
culated the Number Needed to Treat [NNT] as an indicator to measure the effectiveness of
treatments with cancer specific mortality as the outcome [http://www.calctool.org/CALC/prof/
medical/NNT].
Results
Therapy trends in primary non-metastatic prostate cancer
10, 787 men with non-metastatic local disease were identified for this study of whom 422
[3.9%] did not have a documented treatment. The final cohort therefore included 10,365 men;
1435 men treated by RP, 3320 by RT, 3590 by PADT and 2020 by CM [no active treatment].
Over the decade there was a more than 50% reduction in the use of PADT as a treatment mo-
dality [p<0.0001] [Table 1] [Fig. 1]. In contrast, the use of RP had more than doubled
[p<0.0001]. The use of non- active treatment or CM as primary management had also tripled
from 7% to 22% in the same interval [p<0.0001]. RT usage however remained relatively stable
over the decade.
Radical therapy uptake in risk stratified groups
The population was then sub-divided into risk groups based on NICE criteria to investigate the
effect of risk group on therapy trends [Table 2] [Fig. 2]. In low-risk cancers the use of CM
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increased by five-fold over the decade, while uptake of RT and RP fell significantly [p< 0.0001
for both] [Table 2] [Fig. 2]. Intermediate-risk cancers also showed a similar trend with a 1.5–2
fold increase in the use of CM over the decade [p<0.0001]. Here however there was also an in-
crease in the uptake of RP amounting to 17–18% of the cohort in the latter half of the decade
[p<0.0001] [Fig. 2]. RT uptake however remained static in this group [Table 2]. In high-risk
cancers the use of both RP and RT increased significantly [p<0.0001 for both]. RP uptake in-
creased by 3-fold while RT uptake at a more modest rate [Fig. 2]. Use of PADT however fell
across all groups regardless of risk category [Fig. 2].
Radical therapy uptake in risk stratified group subcategorised by age
We next asked how the combination of age and risk-group influenced treatment trends
[Table 3]. Over the decade men 60y with low-risk disease were significantly more likely to be
treated by CM rather than radical therapy [p<0.0001]. Men 60y with high-risk disease
however were more likely to be treated radically with RP instead of RT as primary therapy
[p = 0.009] [Table 3]. Management of intermediate-risk disease remained relatively unchanged.
In men aged 60–69y, low and intermediate-risk disease were also more likely to be managed by
CM towards the end of the decade [p<0.0001 and p<0.028 respectively]. Again men in this
Table 1. Incidence rate changes in prostate cancer treatment modality for non-metastatic disease between 2000–2005 and 2006–20.
Treatment Percentage 2000–2005 Percentage 2006–2010 SE Z p-value Trend
Conservative management 14% 23% 0.00792 -11.651 0.000 Increase
Radical prostatectomy 12% 15% 0.0069 -4.631 0.000 Increase
Radical radiotherapy 32% 32% 0.00932 -0.037 0.970 No Change
PADT 42% 30% 0.00951 13.098 0.000 Decrease
doi:10.1371/journal.pone.0119494.t001
Fig 1. Proportions of men with non-metastatic cancer treated by different modalities in the Anglia
Cancer Network from 2000–2010.
doi:10.1371/journal.pone.0119494.g001
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age group with high-risk disease were more likely to receive RP by the end of the decade
[p< 0.0001] though the proportions treated by RT were unchanged. Amongst intermediate-
risk men there was a trend to reduced use of RT but no change in the proportions of men treat-
ed by RP [Table 3]. In men 70y with low-risk disease CM use nearly doubled in the decade
while rates of all other treatments fell [p<0.0001]. RP uptake increased in intermediate and
high-risk cancers but represented small proportions of men treated [4%]. There was however a
significant increase in men treated by RT for high-risk disease amounting to over a third of this
Table 2. Incidence rate changes in prostate cancer treatment modality for non-metastatic disease stratified by NICE risk group between
2000–2005 and 2006–201.
Treatment Percentage 2000–2005 Percentage 2006–2010 SE Z p-value Trend
low risk Conservative management 35% 66% 0.0255 -12.048 0.000 Increase
Radical prostatectomy 22% 13% 0.0192 4.720 0.000 Decrease
Radical radiotherapy 30% 16% 0.0212 6.819 0.000 Decrease
PADT 13% 6% 0.0149 4.830 0.000 Decrease
Intermediate risk Conservative management 21% 29% 0.0150 -5.110 0.000 Increase
Radical prostatectomy 14% 19% 0.0128 -3.979 0.000 Increase
Radical radiotherapy 36% 35% 0.0163 0.718 0.473 No change
PADT 29% 18% 0.0141 8.192 0.000 Decrease
High risk Conservative management 3% 7% 0.0062 -6.386 0.000 Increase
Radical prostatectomy 8% 13% 0.0088 -6.019 0.000 Increase
Radical radiotherapy 30% 34% 0.0133 -3.194 0.001 Increase
PADT 59% 46% 0.0141 9.530 0.000 Decrease
doi:10.1371/journal.pone.0119494.t002
Fig 2. Proportions of men with non-metastatic cancer treated by different modalities and stratified by NICE risk group from 2000–2010.
doi:10.1371/journal.pone.0119494.g002
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Table 3. Incidence rate changes in prostate cancer treatment modality for non-metastatic disease stratified by age and NICE risk group between
2000–2005 and 2006–2010.
Age Risk Treatment Percentage 2000–2005 Percentage 2006–2010 SE Z p-value Trend
< 60 years Low risk Conservative management 22.5% 53.4% 0.056 -5.717 0.000 Increase
Radical prostatectomy 46.5% 26.1% 0.055 3.719 0.000 Decrease
Radical radiotherapy 26.4% 16.1% 0.047 2.192 0.028 Decrease
PADT 5.6% 4.3% 0.025 0.487 0.626 No change
Intermediate risk Conservative management 5.8% 13.3% 0.034 -2.194 0.028 Increase
Radical prostatectomy 52.1% 55.1% 0.055 -0.560 0.575 No change
Radical radiotherapy 33.9% 27.4% 0.050 1.300 0.194 No change
PADT 8.3% 4.2% 0.025 1.634 0.102 No change
High risk Conservative management 1.3% 5.2% 0.020 -1.990 0.047 Increase
Radical prostatectomy 31.4% 38.1% 0.050 -1.349 0.177 No change
Radical radiotherapy 49.7% 37.2% 0.051 2.417 0.016 Decrease
PADT 17.6% 19.5% 0.041 -0.451 0.652 No change
60–69 Low risk Conservative management 28.2% 61.0% 0.037 -8.877 0.000 Increase
Radical prostatectomy 25.5% 15.9% 0.030 3.212 0.001 Decrease
Radical radiotherapy 37.3% 18.9% 0.033 5.577 0.000 Decrease
PADT 9.1% 4.2% 0.018 2.679 0.007 Decrease
Intermediate risk Conservative management 13.8% 21.4% 0.022 -3.421 0.001 Increase
Radical prostatectomy 23.8% 27.2% 0.025 -1.345 0.179 No change
Radical radiotherapy 49.6% 42.7% 0.028 2.428 0.015 Decrease
PADT 12.9% 8.8% 0.017 2.390 0.017 Decrease
High risk Conservative management 2.0% 4.4% 0.009 -2.567 0.010 Increase
Radical prostatectomy 16.2% 25.9% 0.021 -4.630 0.000 Increase
Radical radiotherapy 46.9% 47.7% 0.025 -0.307 0.759 No change
PADT 34.9% 22.0% 0.023 5.690 0.000 Decrease
70–79 low risk Conservative management 48.9% 79.0% 0.045 -6.692 0.000 Increase
Radical prostatectomy 2.7% 0.0% 0.011 2.532 0.011 Decrease
Radical radiotherapy 24.9% 11.6% 0.036 3.682 0.000 Decrease
PADT 23.5% 9.4% 0.035 4.062 0.000 Decrease
Intermediate risk Conservative management 26.1% 33.9% 0.024 -3.294 0.001 Increase
Radical prostatectomy 1.5% 4.5% 0.009 -3.252 0.001 Increase
Radical radiotherapy 33.5% 35.5% 0.025 -0.808 0.419 No change
PADT 38.9% 26.1% 0.024 5.389 0.000 Decrease
High risk Conservative management 2.0% 5.4% 0.008 -4.077 0.000 Increase
Radical prostatectomy 1.6% 4.0% 0.007 -3.278 0.001 Increase
Radical radiotherapy 26.9% 36.3% 0.020 -4.642 0.000 Increase
PADT 69.5% 54.3% 0.021 7.209 0.000 Decrease
>80+ low risk Conservative management 78.3% 86.7% 0.104 -0.808 0.419 NA
Radical prostatectomy 0.0% 0.0% 0.000 N/A NA
Radical radiotherapy 0.0% 0.0% 0.000 N/A NA
PADT 21.7% 4.7% 0.065 2.622 0.009 NA
Intermediate risk Conservative management 36.2% 58.3% 0.053 -4.129 0.000 NA
Radical prostatectomy 0.0% 0.0% 0.000 N/A NA
Radical radiotherapy 6.6% 5.3% 0.025 0.493 0.622 NA
PADT 57.2% 36.4% 0.053 3.914 0.000 NA
High risk Conservative management 6.3% 14.8% 0.020 -4.186 0.000 NA
Radical prostatectomy 0.0% 0.0% 0.000 N/A NA
Radical radiotherapy 5.3% 5.5% 0.015 -0.098 0.922 NA
PADT 88.4% 79.7% 0.024 3.592 0.000 NA
doi:10.1371/journal.pone.0119494.t003
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cohort by the end of the decade [p<0.0001] [Table 3]. There were no major shifts in treatment
trends in men 80 years and PADT remained the most common treatment for
this demographic.
Comparative cancer mortality outcomes between radical therapies
This study has revealed increasing uptake of RP for intermediate and high-risk local disease.
We asked if this trend was supported by evidence of better cancer-specific survival [CSS] out-
comes compared to RT. Overall cancer mortality from radical therapy [1,435 RP and 3320 RT
treated men] was 2.7%; 3.2% for RT treated men, and 1.7% for RP. Cumulative survival curves
demonstrated overlap between the two groups in the first few years after treatment before be-
ginning to diverge [Fig. 3A]. Men in the RT group however had worse overall survival rates
suggesting significantly more co-morbidity in this group [Fig. 3B]. In multivariate analysis,
predictors of a worse CSS outcome were presentation with high-risk disease or RT as the pri-
mary treatment [Table 4]. To define this better we further stratified the cohort by age and risk-
group. This analysis demonstrated a trend to benefit from surgery but only in the high-risk
younger men [<60y] [p = 0.07] [Table 5]. Age stratified survival plots further illustrated this
point whereby men<60y had demonstrably better CSS rates after RP as compared to RT
[Fig. 4A]. These benefits were less apparent in men aged 60–69y and non-existent in men>70y
[Fig. 4B and 4C]. Finally, we performed a numbers needed to treat [NNT] analysis to quantify
the RP benefit compared to RT. For the whole cohort the NNT by RP instead of RT to save one
cancer death was 67 [Table 6]. This number fell to 19 in men 60y and with high-risk disease.
For all other groups the NNT were in excess of 50 or favoured RT over RP.
Fig 3. Cumulative (A) Cancer specific and (B) Overall survival from radical prostatectomy and radical
radiotherapy.Dashed lines represent 95% confidence intervals.
doi:10.1371/journal.pone.0119494.g003
Table 4. Multivariate analysis of variables predictive of cancer specific mortality from radical therapy.
Variable Hazard Ratio p value
Age (y) 60–69 0.8 (0.4–1.5) 0.5
70–79 0.8 (0.4–1.5) 0.5
Risk group Intermediate 2.8 (0.9–8.4) 0.05
High 8.0 (2.9–22.2) <0.0001
Treatment Radiotherapy 1.9 (1.0–3.3) 0.024
doi:10.1371/journal.pone.0119494.t004
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Table 5. Comparative cancer specific mortality between radical prostatectomy and radical radiotherapy in groups stratified by age and risk type.
Age Risk Type of treatment Prostate cancer specific
mortality per 100000 P-D
MRD [Mortality rate
difference per 100000]
SE Approx.
95% CI
p-value
< 60 years low Radical
prostatectomy
0.00 n/a n/a n/a n/a n/a
Radical
radiotherapy
0.00
intermediate Radical
prostatectomy
0.21 -0.16 0.43 -1.01 0.68 0.683
Radical
radiotherapy
0.38
high Radical
prostatectomy
0.94 -1.89 0.98 -3.81 0.03 0.070
Radical
radiotherapy
2.83
60–69
years
low Radical
prostatectomy
0.00 -0.51 0.30 -1.09 0.07 0.136
Radical
radiotherapy
0.51
intermediate Radical
prostatectomy
0.12 -0.47 0.23 -0.93 -0.02 0.095
Radical
radiotherapy
0.60
high Radical
prostatectomy
1.03 -0.63 0.47 -1.56 0.29 0.224
Radical
radiotherapy
1.66
70–79
years
low Radical
prostatectomy
4.20 4.2 4.2 -4.03 12.42 0.001
Radical
radiotherapy
0.00
intermediate Radical
prostatectomy
0.00 -0.79 0.25 -1.29 -0.3 0.357
Radical
radiotherapy
0.79
high Radical
prostatectomy
1.45 0.26 1.06 -1.82 2.34 0.790
Radical
radiotherapy
1.19
80+ years low Radical
prostatectomy
n/a n/a n/a n/a n/a n/a
Radical
radiotherapy
n/a
intermediate Radical
prostatectomy
n/a n/a n/a n/a n/a n/a
Radical
radiotherapy
2.16
high Radical
prostatectomy
n/a n/a n/a n/a n/a n/a
Radical
radiotherapy
6.35
doi:10.1371/journal.pone.0119494.t005
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Discussion
The key findings of this study in non-metastatic cancers is a global fall in the use of PADT, in-
creased radical therapy for intermediate and high-risk disease and the emergence of non-active
treatment as the commonest option for low-risk cancer. Studies from other investigators have
found both similar and different results. Dinan et al, 2011, in a US study reported a similar fall
in PADT use in men aged 67y between 1999 to 2007 [11]. Concomitantly, the percentage of
men receiving no active treatment increased by 50%. An Australian study of 2,774 men also re-
ported increases in use of CM for low-risk cancer but only in older men [12]. Jacobs et al, 2013,
looked at the use of new radical radiotherapy and surgical techniques in the SEER Cancer Reg-
istry [2004–2009] [13]. Here they found a two-fold increase in the use of these methods in men
with low-risk cancer. This is in contrast to our present study which, while undertaken over a
similar timeframe, actually revealed a fall in the use of radical therapy in low-risk men. Only
one other UK study has explored treatment changes over time. Fairley et al, 2009, reported
changes in therapy in the Northern and Yorkshire region from 2000–2006 [14]. This study also
reported a fall in the use of PADT and increase use of RP but did not separate the outcomes by
risk group. Our study is therefore the first to provide a risk-stratified analysis of treatment
changes in a UK non-metastatic prostate cancer population.
In terms of radical therapy we found age and risk specific shifts for each modality. RT rates
in intermediate and low-risk cancers were trending downwards over the decade but were
Fig 4. Cumulative cancer specific survival from radical prostatectomy and radical radiotherapy in age stratified groups.
doi:10.1371/journal.pone.0119494.g004
Table 6. Data of the numbers needed to treat by radical prostatectomy versus radical radiotherapy to save 1 cancer specific mortality event.
Age <60 years Age 60–69 years Age 70–79 years
low intermediate high low intermediate high low intermediate High
ARR n/a 0.004 0.052 0.015 0.012 0.017 -0.167 0.0182 -0.0055
RRR n/a 0.457 0.702 1 0.808 0.424 infinity 1 -0.2153
NNT n/a 247 19 66 86 59 -6 55 -180
ARR- absolute risk reduction, RRR—relative risk reduction, NNT-numbers needed to treat.
doi:10.1371/journal.pone.0119494.t006
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increasing in men 70y with high-risk disease. The benefits of this change in practice is now
supported by the 2009 and 2011 publications of the SPCG7 and MRC/PRO7 trials showing im-
proved CSS by adding RT to PADT [4–5]. RP uptake, conversely, is rising in younger men with
high-risk disease. This latter change in practice is again supported by recent data [albeit not
randomised] from the EMPACT group and others showing the potential benefits of surgery in
this demographic [15–16]. The absolute benefit of RP over RT however has been a point of
controversy for some time [7, 17–18]. A number of studies have published comparisons but
have been criticised for the lack of an optimal RT regime [17]. A significant strength of our co-
hort is that over 88% of RT patients received concurrent ADT though the radiotherapy dosage
and ADT duration would have evolved over time. Within this context, RP appeared to show an
overall CSS advantage. The main benefit however was in men 60y with high-risk disease
which supports the change in practice observed in our cohort. In NNT analysis only this group
demonstrated a reasonable treatment number to save one cancer death. To our knowledge this
is the first UK study to compare RP and RT outcomes and report this finding. Our study does
need longer follow up given the slow history of the disease but this in fact favours younger men
who will have longer life expectancy. In this context the updated SPCG-4 randomised trial of
RP versus watchful waiting is worth noting [19]. Over the 20 years of follow up the NNT by
RRP has continued to fall and now stands at 8. Here again the main benefits have been seen in
men 65y and with higher risk disease. This study did not include a RT arm and it would
have been intriguing to assess the comparison after such a long follow up. Results from the Pro-
tecT trial may be partly able to address this though most of the men recruited had low and in-
termediate disease [20–21]. The large NNT in our other subgroups suggest that RP confers at
best marginal benefits over RT and this is unlikely to be significantly altered in longer follow
up. This is particularly relevant when considering that RP has been shown to have worse im-
mediate functional debility and impact on quality of life, compared to RT [22–23].
Our study clearly has a number of inherent limitations using as it does registry based infor-
mation though the NCRS [East] is well-known for the accuracy and completeness of its data
collection and collation. We acknowledge that this study only involves a single cancer network
though there are no particular suspicions that our population is very different from the rest of
the UK. As mentioned we could not differentiate between active surveillance and watchful
waiting in men with no active treatment. Finally, our results comparing RP and RT outcomes
is based on relatively short follow up and may become more pronounced as the follow up con-
tinues. We do however believe that our results are more representative of current clinical prac-
tice because of the high percentage of men on combination RT and ADT.
In conclusion, we report a significant shift in the management of non-metastatic prostate
cancer over the last decade in a UK population. Within the limitations of a registry based
study, these results suggest a move towards age and risk-appropriate treatment of non-
metastatic prostate cancer. This is particularly reflected in the increasing use of non-active
treatment for low-risk cancer. We further report an increasing use of RP for younger men with
high-risk disease and demonstrate evidence suggesting a benefit in CSS. Overall these trends
are very encouraging for the goal of tailored treatment for patients but will have implications
for health resource allocation which will need to be considered by service providers.
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